CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-In Capital	Accumulated Other Comprehensive Loss	Retained Earnings	FlexBiosys, Inc.	FlexBiosys, Inc. Common Stock	FlexBiosys, Inc. Additional Paid-In Capital
Balance at Dec. 31, 2022	$ 1,910,700	$ 556	$ 1,547,266	$ (34,394)	$ 397,272
Beginning Balance (in shares) at Dec. 31, 2022		55,557,698
Net income, as restated	35,123				35,123
Conversion of debt	(3)		(3)
Conversion of debt (in shares)		6
Exercise of stock options and vesting of stock units	62	$ 2	60
Exercise of stock options and vesting of stock units (in shares)		176,394
Tax withholding on vesting of restricted stock units	(11,140)	$ (1)	(11,139)
Tax withholding on vesting of restricted stock units (in shares)		(63,238)
Issuance of common stock pursuant to the acquisition						$ 5,243		$ 5,243
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229		7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense as restated	12,737		12,737
Translation adjustment	(3,092)			(3,092)
Balance at Jun. 30, 2023	1,956,859	$ 557	1,561,393	(37,486)	432,395
Ending Balance, as restated (in shares) at Jun. 30, 2023		55,744,896
Balance at Mar. 31, 2023	1,926,714	$ 556	1,544,956	(31,407)	412,609
Beginning Balance (in shares) at Mar. 31, 2023		55,644,301
Net income, as restated	19,786				19,786
Conversion of debt	(3)		(3)
Conversion of debt (in shares)		6
Exercise of stock options and vesting of stock units	33	$ 1	32
Exercise of stock options and vesting of stock units (in shares)		36,184
Tax withholding on vesting of restricted stock units	(1,547)		(1,547)
Tax withholding on vesting of restricted stock units (in shares)		(9,631)
Issuance of common stock pursuant to the acquisition						$ 5,243		$ 5,243
Issuance of common stock pursuant to the acquisition, (in shares)							31,415
Issuance of common stock pursuant to contingent consideration earnout payment	7,229		7,229
Issuance of common stock pursuant to contingent consideration earnout payments		42,621
Stock-based compensation expense as restated	5,483		5,483
Translation adjustment	(6,079)			(6,079)
Balance at Jun. 30, 2023	1,956,859	$ 557	1,561,393	(37,486)	432,395
Ending Balance, as restated (in shares) at Jun. 30, 2023		55,744,896
Balance at Dec. 31, 2023	1,964,845	$ 558	1,569,227	(37,808)	432,868
Beginning Balance (in shares) at Dec. 31, 2023		55,766,078
Net income, as restated	9,009				9,009
Conversion of debt	(107)		(107)
Conversion of debt (in shares)		2
Exercise of stock options and vesting of stock units	1,788	$ 2	1,786
Exercise of stock options and vesting of stock units (in shares)		152,481
Tax withholding on vesting of restricted stock units	(8,857)	$ (1)	(8,856)
Tax withholding on vesting of restricted stock units (in shares)		(47,109)
Issuance of common stock pursuant to contingent consideration earnout payment	5,742		5,742
Issuance of common stock pursuant to contingent consideration earnout payments		31,408
Stock-based compensation expense as restated	18,655		18,655
Translation adjustment	(6,637)			(6,637)
Balance at Jun. 30, 2024	1,984,438	$ 559	1,586,447	(44,445)	441,877
Ending Balance, as restated (in shares) at Jun. 30, 2024		55,902,860
Balance at Mar. 31, 2024	1,965,592	$ 559	1,571,811	(42,942)	436,164
Beginning Balance (in shares) at Mar. 31, 2024		55,841,318
Net income, as restated	5,713				5,713
Conversion of debt	(53)		(53)
Conversion of debt (in shares)		2
Exercise of stock options and vesting of stock units	842		842
Exercise of stock options and vesting of stock units (in shares)		40,560
Tax withholding on vesting of restricted stock units	(1,234)		(1,234)
Tax withholding on vesting of restricted stock units (in shares)		(7,658)
Issuance of common stock pursuant to contingent consideration earnout payment	5,202		5,202
Issuance of common stock pursuant to contingent consideration earnout payments		28,638
Stock-based compensation expense as restated	9,879		9,879
Translation adjustment	(1,503)			(1,503)
Balance at Jun. 30, 2024	$ 1,984,438	$ 559	$ 1,586,447	$ (44,445)	$ 441,877
Ending Balance, as restated (in shares) at Jun. 30, 2024		55,902,860